Risk of prostate cancer death in men diagnosed with prostate cancer at cystoprostatectomy. A nationwide population-based study
DOI:
https://doi.org/10.2340/sju.v59.40001Keywords:
Bladder cancer, cystoprostatectomy, incidental prostate cancer, risk of deathAbstract
Background and aims: One out of three men who undergo cystoprostatectomy for bladder cancer is diagnosed with incidental prostate cancer (PCa) at histopathological examination. Many of these men are PSA tested as part of their follow-up, but it is unclear if this is needed. The aim of this study was to assess the risk of PCa death in these men and the need of PSA-testing during follow-up.
Methods: Between 2002 and 2020, 1,554 men were diagnosed with PCa after cystoprostatectomy performed for non-metastatic bladder cancer and registered in the National Prostate Cancer Register (NPCR) of Sweden. We assessed their risk of death from PCa, bladder cancer and other causes up to 15 years after diagnosis by use of data in The Cause of Death Register. The use of androgen deprivation therapy (ADT) as a proxy for PCa progression was assessed by fillings in The Prescribed Drug Register.
Results: Fifteen years after diagnosis, cumulative incidence of death from PCa was 2.6% (95% CI 2.3%–2.9%), from bladder cancer 32% (95% CI: 30%–34%) and from other causes 40% (95% CI: 36%–44%). Only 35% of men with PCa recorded as primary cause of death in The Cause of Death Register had started ADT before date of death, indicating sticky-diagnosis bias with inflated risk of PCa death.
Conclusions: For a large majority of men diagnosed with incidental PCa at cystoprostatectomy performed for bladder cancer, the risk of PCa death is very small so there is no rationale for PSA testing during follow-up.
Downloads
References
Bell KJL, Del Mar C, Wright G, et al. Prevalence of incidental prostate cancer: a systematic review of autopsy studies. Int J Cancer. 2015;137(7):1749–1757.
https://doi.org/10.1002/ijc.29538 DOI: https://doi.org/10.1002/ijc.29538
Fahmy O, Khairul-Asri MG, Schubert T, et al. Clinicopathological features and prognostic value of incidental prostatic adenocarcinoma in radical cystoprostatectomy specimens: a systematic review and meta-analysis of 13,140 patients. J Urol. 2017;197(2):385–390.
https://doi.org/10.1016/j.juro.2016.08.088 DOI: https://doi.org/10.1016/j.juro.2016.08.088
Bruins HM, Djaladat H, Ahmadi H, et al. Incidental prostate cancer in patients with bladder urothelial carcinoma: comprehensive analysis of 1,476 radical cystoprostatectomy specimens. J Urol. 2013;190(5):1704–1709.
https://doi.org/10.1016/j.juro.2013.05.034 DOI: https://doi.org/10.1016/j.juro.2013.05.034
Thomas C, Giesswein A, Hainz M, et al. Concomitant gleason Score ≥7 prostate cancer is an independent prognosticator for poor survival in nonmetastatic bladder cancer patients undergoing radical cystoprostatectomy. Int Urol Nephrol. 2015;47(11):1789–1796.
https://doi.org/10.1007/s11255-015-1110-1 DOI: https://doi.org/10.1007/s11255-015-1110-1
Heidegger I, Oberaigner W, Horninger W, et al. High incidence of clinically significant concomitant prostate cancer in patients undergoing radical cystectomy for bladder cancer: a 10-year single-center experience. Urol Oncol. 2017;35(4):152.e1–5.
https://doi.org/10.1016/j.urolonc.2016.11.004 DOI: https://doi.org/10.1016/j.urolonc.2016.11.004
Liedberg F, Kjellström S, Lind AK, et al. Swedish National Guidelines on Urothelial Carcinoma: 2021 update on non-muscle invasive bladder cancer and upper tract urothelial carcinoma. Scand J Urol. 2022;56(2):137–146.
https://doi.org/10.1080/21681805.2022.2041086 DOI: https://doi.org/10.1080/21681805.2022.2041086
Bratt O, Carlsson S, Fransson P, et al. The Swedish national guidelines on prostate cancer, part 1: early detection, diagnostics, staging, patient support and primary management of non-metastatic disease. Scand J Urol. 2022;56(4):265–273.
https://doi.org/10.1080/21681805.2022.2094462 DOI: https://doi.org/10.1080/21681805.2022.2094462
Bratt O, Carlsson S, Fransson P-A, et al. The Swedish national guidelines on prostate cancer, part 2: recurrent, metastatic and castration-resistant disease. Scand J Urol. 2022;56(4):278–284.
https://doi.org/10.1080/21681805.2022.2093396 DOI: https://doi.org/10.1080/21681805.2022.2093396
Van Hemelrijck M, Garmo H, Wigertz A, et al. Cohort profile update: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base—a refined prostate cancer trajectory. Int J Epidemiol. 2015;45(1):73–82.
https://doi.org/10.1093/ije/dyv305 DOI: https://doi.org/10.1093/ije/dyv305
Tomić K, Sandin F, Wigertz A, et al. Evaluation of data quality in the National Prostate Cancer Register of Sweden. Eur J Cancer. 2015;51(1):101–111.
https://doi.org/10.1016/j.ejca.2014.10.025 DOI: https://doi.org/10.1016/j.ejca.2014.10.025
Tomić K, Berglund A, Robinson D, et al. Capture rate and representativity of The National Prostate Cancer Register of Sweden. Acta Oncol. 2014;54(2):158–163.
https://doi.org/10.3109/0284186X.2014.939299 DOI: https://doi.org/10.3109/0284186X.2014.939299
Ludvigsson JF, Appelros P, Askling J, et al. Adaptation of the Charlson Comorbidity Index for register-based research in Sweden. Clin Epidemiol. 2021;13:21–41.
https://doi.org/10.2147/CLEP.S282475 DOI: https://doi.org/10.2147/CLEP.S282475
R Core Team. R: A language and environment for statistical computing [Internet]. R Foundation for Statistical Computing, Vienna, Austria; 2022. [cited 14-12-2023] Available from: https://www.R-project.org/
Svenska Nationella Kvalitetsregistret för urinblåse-och urinvägscancer (SNRUBC). SNRUBC [Internet]. 2023 [cited 14-12-2023]. Available from: https://statistik.incanet.se/Urinblasecancer/
Cancerregistret. Socialstyrelsen [Internet]. 2023 [cited 14-12-2023]. Available from: https://www.socialstyrelsen.se/statistik-och-data/register/cancerregistret/
Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11(1):450.
https://doi.org/10.1186/1471-2458-11-450 DOI: https://doi.org/10.1186/1471-2458-11-450
Barlow L, Westergren K, Holmberg L, et al. The completeness of the Swedish Cancer Register – a sample survey for year 1998. Acta Oncol. 2009;48(1):27–33.
https://doi.org/10.1080/02841860802247664 DOI: https://doi.org/10.1080/02841860802247664
Fall K, Strömberg F, Rosell J, et al. Reliability of death certificates in prostate cancer patients. Scand J Urol Nephrol. 2008;42(4):352–357.
https://doi.org/10.1080/00365590802078583
Godtman R, Holmberg E, Stranne J, et al. High accuracy of Swedish death certificates in men participating in screening for prostate cancer: acomparative study of official death certificates with a cause of death committee using a standardized algorithm. Scand J Urol Nephrol. 2011;45(4):226–232. DOI: https://doi.org/10.3109/00365599.2011.559950
https://doi.org/10.1080/00365590802078583 DOI: https://doi.org/10.1080/00365590802078583
Pignot G, Salomon L, Neuzillet Y, et al. Clinicopathological characteristics of incidental prostate cancer discovered from radical cystoprostatectomy specimen: a multicenter French study. Ann Surg Oncol. 2013;21(2):684–690.
https://doi.org/10.1245/s10434-013-3340-8 DOI: https://doi.org/10.1245/s10434-013-3340-8
Packiam VT, Tsivian M, Avulova S, et al. Long-term outcomes of incidental prostate cancer at radical cystectomy. Urol Oncol. 2020;38(11):848.e17–22.
https://doi.org/10.1016/j.urolonc.2020.05.018 DOI: https://doi.org/10.1016/j.urolonc.2020.05.018
Liedberg F, Anderson H, Bläckberg M, et al. Prospective study of transitional cell carcinoma in the prostatic urethra and prostate in the cystoprostatectomy specimen. Scand J Urol Nephrol. 2007;41(4):290–296.
https://doi.org/10.1080/00365590601183576 DOI: https://doi.org/10.1080/00365590601183576
Kimura T, Sato S, Takahashi H, et al. Global trends of latent prostate cancer in autopsy studies. Cancers. 2021;13(2):359.
https://doi.org/10.3390/cancers13020359 DOI: https://doi.org/10.3390/cancers13020359
Bergengren O, Westerberg M. Watch out for sticky diagnosis bias in older men with prostate cancer. Scand J Urol. 2022;56(5–6):365–366.
https://doi.org/10.1080/21681805.2022.2124305 DOI: https://doi.org/10.1080/21681805.2022.2124305
Orrason AW, Styrke J, Garmo H, Stattin P. Evidence of cancer progression as the cause of death in men with prostate cancer in Sweden. BJU Int. 2023;131(4):486–493.
https://doi.org/10.1111/bju.15891 DOI: https://doi.org/10.1111/bju.15891
Löffeler S, Halland A, Weedon-Fekjær H, et al. High Norwegian prostate cancer mortality: evidence of over-reporting. Scand J Urol. 2018;52(2):122–128.
https://doi.org/10.1080/21681805.2017.1421260 DOI: https://doi.org/10.1080/21681805.2017.1421260
Innos K, Paapsi K, Alas I, et al. Evidence of overestimating prostate cancer mortality in Estonia: a population-based study. Scand J Urol. 2022;56(5–6):359–364.
https://doi.org/10.1080/21681805.2022.2119274 DOI: https://doi.org/10.1080/21681805.2022.2119274
Lycken M, Drevin L, Garmo H, et al. The use of palliative medications before death from prostate cancer: a Swedish population-based study with a comparative overview of European data. Eur J Cancer. 2018;88:101–108.
https://doi.org/10.1016/j.ejca.2017.10.023 DOI: https://doi.org/10.1016/j.ejca.2017.10.023
Thomsen FB, Garmo H, Brasso K, et al. Temporal changes in cause-specific death in men with localised prostate cancer treated with radical prostatectomy: a population-based, nationwide study. J Surg Oncol. 2021;124(5):867–875.
https://doi.org/10.1002/jso.26579 DOI: https://doi.org/10.1002/jso.26579
van den Bergh RCN, van Casteren NJ, van den Broeck T, et al. Role of hormonal treatment in prostate cancer patients with nonmetastatic disease recurrence after local curative treatment: a systematic review. Eur Urol. 2016;69(5):802–820.
https://doi.org/10.1016/j.eururo.2015.11.023 DOI: https://doi.org/10.1016/j.eururo.2015.11.023
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Pietro Scilipoti, Fredrik Liedberg, Hans Garmo, Andri Wilberg Orrason, Pär Stattin, Marcus Westerberg
This work is licensed under a Creative Commons Attribution 4.0 International License.
Acta Chirurgica Scandinavica Society owns the copyright for all material published until Volume 57 (2023) unless otherwise specified. As from Volume 59 (2024) all published articles, unless otherwise specified, are published under CC-BY licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, with the condition of proper attribution to the original work.
